Author(s):
Miranda-Lourenço, Catarina ; Ribeiro Rodrigues, Leonor ; Fonseca-Gomes, João ; Tanqueiro, Sara ; Belo, Rita F. ; Ferreira, Catarina B. ; Rei, Nádia ; Ferreira-Manso, Mafalda ; de Almeida-Borlido, Carolina ; Costa-Coelho, Tiago ; Freitas, Céline ; Zavalko, Svitlana ; Mouro, Francisco ; Sebastião, Ana M ; Xapelli, Sara ; Rodrigues, Tiago M. ; Diógenes, Maria José
Date: 2020
Persistent ID: http://hdl.handle.net/10451/47282
Origin: Repositório da Universidade de Lisboa
Subject(s): Brain-derived neurotrophic factor (BDNF); Adenosine; TrkB receptor; Alzheimer’s disease; Amyotrophic lateral sclerosis; Rett Syndrome
Description
Neurotrophins are a well-known family of neurotrophic factors that play an important role both in the central and peripheral nervous systems, where they modulate neuronal survival, development, function and plasticity. Brain-derived neurotrophic factor (BDNF) possesses diverse biological functions which are mediated by the activation of two main classes of receptors, the tropomyosin-related kinase (Trk) B and the p75 neurotrophin receptor (p75NTR). The therapeutic potential of BDNF has drawn attention since dysregulation of its signalling cascades has been suggested to underlie the pathogenesis of both common and rare diseases. Multiple strategies targeting this neurotrophin have been tested; most have found obstacles that ultimately hampered their effectiveness. This review focuses on the involvement of BDNF and its receptors in the pathophysiology of Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS) and Rett Syndrome (RTT). We describe the known mechanisms leading to the impairment of BDNF/TrkB signalling in these disorders. Such mechanistic insight highlights how BDNF signalling compromise can take various shapes, nearly disease-specific. Therefore, BDNF-based therapeutic strategies must be specifically tailored and are more likely to succeed if a combination of resources is employed.
